PharmTech Drug Digest 11.20
News|Articles|February 2, 2006

Dow AgroSciences Receives Regulatory Approval for Plant-Made Vaccine

Dow AgroSciences Receives Regulatory Approval for Plant-Made Vaccine

Dow AgroSciences LLC (Indianapolis, IN, www.dowagro.com), a wholly owned subsidiary of The Dow Chemical Company (Midland, MI, www.dow.com), has received regulatory approval for a plant-cell-culture-derived vaccine from the US Department of Agriculture Center for Veterinary Biologics.

The vaccine is produced from the “DowAgroSciences Concert Plant-Cell-Produced System” that uses plant cells instead of whole plants in a biocontained environment to produce vaccines. With the approval, Dow AgroSciences says that it can focus its efforts on developing vaccines for animal health and that using this technology for human vaccines is a possibility.


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.